He says iblue will be the standard of care but doesn't even talk about ired which will blow blue out of the water a few years or so down the road. And we have both technologies. Diagnostics are improving rapidly so once they get the markers for the cancers that IME is used for then the ability to know when/if iblue did the job will be the double punch to cancers.
Dr. Stanley J Swierzewski offered the following comments: "As a practicing urologist, I invested in Imagin because I have a duty and responsibility to advance any improvements in treatment and technology that will benefit my patients and save lives. Current technology is cumbersome and time consuming, taking a full hour of prep time as opposed to 10 minutes, making it less effective as a screening or follow-up tool. Bladder cancer patients are basically monitored for life with in-office cystoscopies which are not effective in differentiating between inflammation and cancer. To be safe, we perform surgery on many patients which often turns out to be negative. Imagin's i/Blue technology, given its potential speed and sensitivity, will help us assess the patient's condition more quickly and accurately and avoid unnecessary surgery. It will also make necessary surgery more successful, ultimately saving lives and reducing medical expenses. I'm confident that using the i/Blue system will become the standard of care. I look forward to the Research Study results and I cannot wait to use this technology in treating my bladder cancer patients."
I blew my .08 pp out the door at .11 and replaced it with the .05 so my cost base is .02.
News 
Market Data 
Discover 
